P1.01-012 Ceritinib in Anaplastic Lymphoma Kinase (ALK)+ NSCLC Patients Pretreated With Only Crizotinib: ASCEND-1 Subgroup Analysis

Authors :: D.S.W. Tan
Alice T. Shaw
D.R. Camidge
Laura Q.M. Chow
Ranee Mehra
Martin Schuler
Patrick Urban
Ben Solomon
D. Kim
Enriqueta Felip
C. Ortmann
I. Malet
G. J. Riely
Source :: Journal of Thoracic Oncology. 12:S1896-S1897
Publication Year :: 2017
Publisher :: Elsevier BV, 2017.

Subjects :: Pulmonary and Respiratory Medicine
Oncology
Crizotinib
Ceritinib
business.industry
medicine
Cancer research
Anaplastic lymphoma kinase
Subgroup analysis
business
medicine.drug

Tools